Cantargia

Investment summary

Cantargia is developing antibodies against IL1RAP. In December 2019, the company reported interim data from the ongoing three-arm Phase IIa study with CAN04 (targets IL-1 signalling pathway) in combination with first-line chemotherapy in NSCLC and pancreatic cancer. 4/7 evaluable pancreatic cancer patients achieved partial response and 2/3 evaluable NSLC patients achieved an objective response (one complete and one partial response). The results compare favourably to historical response rates to standalone chemotherapy regimens (23% in PDAC; 22–28% in first-line NSCLC). More interim data will be presented in 2020, while final efficacy data are expected in 2021. Cantargia also plans to initiate a Phase Ib trial in the US with CAN04 in combination with a checkpoint inhibitor. Recently, Cantargia introduced CAN10, a preclinical project in inflammation uniquely targeting three interleukin pathways, IL-1, IL-33 and IL-36.